Is Xencor Inc (XNCR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 22.6% / 30% | 66.0% / 30% | 3.5% / 30% | 21.92% / 5% | ✗ NOT HALAL |
| DJIM | 22.6% / 33% | 66.0% / 33% | 3.5% / 33% | 21.92% / 5% | ✗ NOT HALAL |
| MSCI | 21.4% / 33% | 62.6% / 33% | 3.3% / 33% | 21.92% / 5% | ✗ NOT HALAL |
| S&P | 22.6% / 33% | 66.0% / 33% | 3.5% / 33% | 21.92% / 5% | ✗ NOT HALAL |
| FTSE | 21.4% / 33% | 62.6% / 33% | 3.3% / 50% | 21.92% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -90.7% | |
| Operating Margin | -189.9% | |
| Net Margin | -73.2% | |
| Return on Equity (ROE) | -14.1% | |
| Return on Assets (ROA) | -12.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$135M |
| Free Cash Flow | -$138M |
| Total Debt | $188M |
| Debt-to-Equity | 29.5 |
| Current Ratio | 6.3 |
| Total Assets | $875M |
Price & Trading
| Last Close | $12.31 |
| 50-Day MA | $12.10 |
| 200-Day MA | $11.79 |
| Avg Volume | 728K |
| Beta | 1.0 |
|
52-Week Range
$6.92
| |
About Xencor Inc (XNCR)
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Xencor Inc (XNCR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Xencor Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Xencor Inc's debt ratio?
Xencor Inc's debt ratio is 22.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.4%.
What are Xencor Inc's key financial metrics?
Xencor Inc has a market capitalization of $838M, and revenue of $126M. The company maintains a gross margin of -90.7% and a net margin of -73.2%. Return on equity stands at -14.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.